Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Arena Pharmaceuticals

Shares of Arena hit a 52-week high on Tuesday of $7.75. The stock's 52-week low of $1.23 was set on Oct. 4.

"Arena raised gross proceeds of $69.6 million bringing pro forma cash to ~$154 million, which we estimate is sufficient to gain Lorcaserin approval," Piper Jaffray analysts wrote in a May 29 report. "Earlier this month, the Endocrinologic and Metabolic Drugs Advisory Committee voted 18 to 4 to approve Lorcaserin for the treatment of obesity. The drug's PDUFA date is June 27th, but could potentially be pushed back 90 days. Regardless, we do anticipate approval this year triggering a $60 million milestone from partner Eisai. We reiterate our Overweight rating and $7 price target."

Five of the 11 analysts who cover Arena rated it hold. Four analysts gave the stock a buy rating and two rated it sell.

The stock has risen 311.81% year to date.

-- Written by Alexandra Zendrian

>To contact the writer of this article, click here: Alexandra Zendrian

>To submit a news tip, send an email to:

>To follow the writer on Twitter, go to Alexandra Zendrian.

If you liked this article you might like

STMicroelectronics, Intercept Pharmaceuticals: 'Mad Money' Lightning Round

Watch Out For the Dominoes That Fall: Cramer's 'Mad Money' Recap (Wed 9/20/17)

These Stocks Pay You to Own Them

From the Marlboro Man to Vaping, Here Are the Events that Shaped Big Tobacco

Tobacco Stocks Mixed as FDA Launches Campaign to Keep Kids Away From E-Cigarettes